This distinction can influence treatment response, particularly in immunotherapy, highlighting the need for tailored strategies and prospectively stratifying by EBV status Although immunotherapy has shown substantial promise, not all patients respond, and predictive biomarkers, such as PD-L1 expression, tumor mutational burden, and circulating EBV DNA, remain under investigation and require clinical validation [111,112]. Here, CD274 is linked to neoplasm.